Sheila A. Mathias
Chief Scientific OfficerDr. Sheila A. Mathias, J.D., M.B.A. & Ph.D., serves as Chief Scientific Officer at Virpax Pharmaceuticals, Inc. since April 7, 2021. She has many leadership experience in the pharmaceutical industry accelerating drug development. She was Senior Director Global Regulatory Affairs at Sun Pharma Advanced Research Company from 2018 to 2021. Sheila has held increasing roles of responsibilities, entering the pharmaceutical industry at Merck US Human Health in the position of Medical Science Liaison. Dr. Mathias transitioned into Regulatory Affairs at Aventis Pharmaceuticals and has successfully brought multiple products through regulatory approval. Dr. Mathias received a B.S in Zoology from Howard University, a Ph.D. in Neurophysiology from Meharry Medical College, an executive MBA from Saint Joseph’s University and a JD from Northwestern California University School of Law. Since 2018, she has served on the Advisory Board for Tennessee State University Department of Biology. Her experience includes roles at Braeburn Pharmaceuticals from 2015 to 2018, Otsuka Pharmaceuticals from 2013 to 2018, Actelion Clinical Research from 2012 to 2013, Cephalon from 2007 to 2011, Novartis Pharmaceuticals from 2005 to 2007 and Aventis Pharmaceuticals from 2002 to 2005.
Positions
- Company NameVirpax Pharmaceuticals, Inc.Stock CodeVRPXPositionChief Scientific Officer
